2 patents currently held
95 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Jun 2033. from the record
Of the 95 now held by other companies, 78 name Université Paris Cité as their current owner, and 17 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2033
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jun 2033 · High confidence
Also notable
Ends Jul 2037 · High confidence
Method and Pharmaceutical Composition for Use in the Treatment of Cancer
US 9,198,949
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2033.
Compositions Useful for Mucosal Healing
US 11,389,470
Granted 2022. Computed term ends 2037.
Formerly held, still cited
Notable
Ends Apr 2034 · High confidence
Cited by 13 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2034.
now held by Université Paris Cité
Also notable
Ends Feb 2035 · High confidence
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
now held by Universite de Paris
Also notable
Ends Jun 2037 · High confidence
The earliest of the three still in force, granted 2021 and renewed since. Its term ends first, in 2037.
now held by Université Paris Cité
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 1, 2027The maintenance fee for Method and Pharmaceutical Composition for Use in the Treatment of Cancer (US 9,198,949) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
Recent changes
- 3 terms have ended since Aug 19, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions Useful for Mucosal Healing | 1 in force | to Jul 2037 |
| Method and Pharmaceutical Composition for Use in the Treatment of Cancer | 1 in force | to Jun 2033 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,198,949 | Method and Pharmaceutical Composition for Use in the Treatment of Cancer held by Inserm (Institut National de la Sante et de la Recherche Medicale), Universite Pierre et Marie Curie Upmc, Universite Paris Diderot-Paris 7, Universite Paris Descartes and Assistance Publique-Hopitaux de Paris In force · High confidence | In force | High confidence | |
| US 11,389,470 | Compositions Useful for Mucosal Healing held by Universite de Paris In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 95 patents in force now held by others · 49 patents ended · 4 applications pending · 95 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed